That metabolic phenotype can dictate the function of macrophages has been widely demonstrated in vitro, however in vivo relevance of these findings has been lacking. Sverdberg et al., observe that the in vivo microenvironment shapes the ability of macrophages to utilize glucose and thus affects their responsiveness to stimuli.
In type 2 cellular immune responses, such as allergy or helminth infection, IL-4 production results in the polarization of macrophages resulting in a distinct phenotype M(IL-4) characterised by the expression of arginase-1 as well as factors involved in tissue repair, and antiinflammatory mediators [14] . Using markers recently described [2, 15, 16] , and highly specific, gating strategy to differentiate IMs and AMs, Svedberg et al. [13] , observed that AMs were less responsive than IMs in vivo, following systemic or local administration of IL-4. AM hyporesponsiveness to IL-4 was confirmed in mice infected with the rodent helminth Nippostrongylus brasiliensis, which elicits the potent production Immunometabolism. 2020;2(1):e200007. https://doi.org/10.20900/immunometab20200007 Immunometabolism 3 of 8 of IL-13 and IL-4 in the lung resulting in the activation of M(IL-4) that facilitate tissue repair and provide protection against reinfection [17, 18] .
Svedberg et al. [13] , report that AMs, contrary to IMs, fail to expand or express typical markers of M(IL-4) following infection. The differential responsiveness of AM and IM to available IL-4 could result from the distinct ontogeny or environmental niche of these cells. To address this issue, Svedberg et al. [13] purified AMs from the lungs of naive mice and cultured them in vitro. Cultured AMs altered their gene expression profile and regained responsiveness to IL-4. This key experiment provides proof that the alveolar space constitutes a unique environment responsible for dictating the in vivo responsiveness of these cells. This finding was further corroborated by an experiment in which peritoneal macrophages (PECs) were delivered by intranasal instillation into naïve mice, following which they adopted a phenotype similar to that of AMs, and failed to respond to IL-4.
By comparing the transcriptomic profile in response to IL-4 of AMs, IMs and PECs, Svedberg et al. [13] , identified that metabolic reprogramming occurs in PECs but that few metabolic pathways were altered in response [21] . OXPHOS metabolism in AMs has previously been reported to be enhanced as compared to IMs [22, 23] , due to the degradation of the surfactant molecule (SP-A/SP-D) in the airways which are enriched in lipids. Enhanced OXPHOS in AMs, as compared to IMs, was proposed to explain why these cells are able to sustain their energy production in a glucose-deprived environment [22] . In the light of those [ 13] , treated AMs in vitro with 2DG to block glycolysis. Whilst cultured AMs regain their responsiveness to IL-4, AMs treated with 2DG failed to do so, corroborating the hypothesis that reduced glycolysis contributes to the unresponsiveness of AMs to IL-4 [9, 24] . 2DG can also impact OXPHOS [25] , however since interference of the OXPHOS pathway with etomoxir did not impact on the phenotype of AM it is more likely that the ability of 2DG to block glycolysis is responsible for its effect. While the authors did not identify the specific component of the niche that drives the hyporesponsiveness of AMs to IL-4, a possibility is that the low glucose availability in the airways [26] predisposes these cells to rely less heavily on glycolysis. Indeed, Davies et al, 2018 [27] suggest that the metabolite be that the hypo-responsiveness to IL-4 has evolved to limit the pathologies associated with uncontrolled or persistent type 2 immune responses, such as asthma. In line with this idea, it is interesting to note that whilst AMs do not respond to IL-4, resting AMs express many genes usually considered as being part of the type 2 profile.
The importance of work addressing the role of the niche factors in macrophage polarisation is highlighted by the increasing interest in targeting macrophages to promote wound repair, improve infection outcomes or prevent fibrosis [12, 28] . As we develop a greater understanding of macrophage metabolism and how it shapes the response of these cells, we may also be able to harness immunometabolism for therapeutic purposes [19, 29, 30] . Evidence stemming from cancer therapeutics indeed show that alteration of tissue metabolism can influence pathophysiological and immunological responses. One of these examples is treatment with Metformin, which modulates FAO, that has been shown to improve clinical outcomes in both cancer and in preclinical models of tuberculosis [31] . In terms of respiratory disease, elevated glucose in the airways has been associated with pathological conditions associated with uncontrolled type 2 responses including asthma and Chronic obstructive pulmonary disease), and it is tempting to speculate that treatments interfering with glucose uptake or metabolism could restore the IL-4 hypo-responsiveness of AMs and potentially alleviate disease symptoms. Such treatments (e.g., 2-DG, Ritonavir which affects glucose transporter-1 or FXII that targets lactate dehydrogenase) have already been used pre-clinically in cancer models, and are ripe for application in other disease contexts. The challenge for the future will be in leveraging the knowledge of how macrophages metabolically adapt to unique tissue niches, and how we can exploit this knowledge to develop tissue-specific therapeutic strategies.
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